同行比较信函对老年及残障成人中高开具量喹硫平初级保健处方者的影响:一项随机临床试验
该随机临床试验针对2013至2014年全国范围内开具喹硫平量最高的5055名初级保健处方者,将其1:1随机分配接受安慰剂信函或3封同行比较信函。结果显示,干预组在9个月内每名处方者供应的喹硫平日数减少11.1%,且效果持续至2年;患者层面喹硫平接收日数减少3.9%,低价值适应症患者降幅更大,未发现替代其他抗精神病药、死亡率或住院使用差异。
要点
- 同行比较信函使高开具量初级保健处方者的喹硫平供应日数在9个月内减少11.1%,并持续至2年。
- 患者层面喹硫平接收日数减少3.9%,低价值适应症患者降幅大于指南一致适应症患者。
- 未发现替代其他抗精神病药的证据,9个月死亡率与住院使用两组相似。
核心结论
- 同行比较信函导致喹硫平处方量大幅且持久减少,未发现对患者的负面效应。
研究设计与样本
- 随机临床试验(意向性治疗分析),2015至2017年在全国医疗保险计划中针对5055名2013和2014年喹硫平开具量最高的初级保健处方者(约占所有初级保健喹硫平处方者的5%)。
- 处方者按1:1随机接受安慰剂信函或3封同行比较信函,信函指出其喹硫平处方量相对同行较高且正受医疗保险审查。
主要发现
- 9个月内干预组每名处方者供应的喹硫平日数较对照组减少11.1%(2456 vs 2864天;百分比差异,减少11.1%;95% CI,-13.1%至-9.2%;P < .001;校正差异,-319天;95% CI,-374至-263天;P < .001),并持续至2年(减少15.6%;95% CI,-18.1%至-13.0%;P < .001)。
- 患者层面,干预组个体在9个月内从所有处方者处接收的喹硫平日数减少3.9%(95% CI,-5.0%至-2.9%;P < .001)。
- 低价值适应症患者较指南一致适应症患者降幅更大(-5.9% [95% CI,-8.0%至-3.9%] vs -2.4% [95% CI,-4.0%至-0.9%],两组效应相等的检验 P = .01)。
- 未发现替代其他抗精神病药的证据,9个月死亡率和住院使用在治疗组与对照组之间相似。
临床怎么用
- 针对高开具量初级保健处方者发送同行比较信函可作为减少喹硫平超适应症处方的有效策略。
- 干预措施未增加其他抗精神病药替代,且未观察到死亡率或住院使用的负面影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antipsychotic agents, such as quetiapine fumarate, are frequently overprescribed for indications not supported by clinical evidence, potentially causing harm. OBJECTIVE: To investigate if peer comparison letters targeting high-volume primary care prescribers of quetiapine meaningfully reduce their prescribing. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial (intent to treat) conducted from 2015 to 2017 of prescribers and their patients nationwide in the Medicare program. The trial targeted the 5055 highest-volume primary care prescribers of quetiapine in 2013 and 2014 (approximately 5% of all primary care prescribers of quetiapine). INTERVENTIONS: Prescribers were randomized (1:1 ratio) to receive a placebo letter or 3 peer comparison letters stating that their quetiapine prescribing was high relative to their peers and was under review by Medicare. MAIN OUTCOMES AND MEASURES: The primary outcome was the total quetiapine days supplied by prescribers from the intervention start to 9 months. Secondary outcomes included quetiapine receipt from all prescribers by baseline patients, quetiapine receipt by patients with low-value or guideline-concordant indications for therapy, mortality, and hospital use. In exploratory analyses, the study followed outcomes to 2 years. RESULTS: Of the 5055 prescribers, 231 (4.6%) were general practitioners, 2428 (48.0%) were in family medicine, and 2396 (47.4%) were in internal medicine; 4155 (82.2%) were male. All were included in the analyses. Over 9 months, the treatment arm supplied 11.1% fewer quetiapine days per prescriber vs the control arm (2456 vs 2864 days; percentage difference, 11.1% fewer days; 95% CI, -13.1% to -9.2% days; P < .001; adjusted difference, -319 days; 95% CI, -374 to -263 days; P < .001), which persisted through 2 years (15.6% fewer days; 95% CI, -18.1% to -13.0%; P < .001). At the patient level, individuals in the treatment arm received 3.9% (95% CI, -5.0% to -2.9%; P < .001) fewer days of quetiapine from all prescribers over 9 months, with a larger decrease among patients with low-value vs guideline-concordant indications (-5.9% [95% CI, -8.0% to -3.9%] vs -2.4% [95% CI, -4.0% to -0.9%], P = .01 for test that effects were equal for both patient groups). There was no evidence of substitution to other antipsychotics, and 9-month mortality and hospital use were similar between the treatment vs control arms. CONCLUSIONS AND RELEVANCE: Peer comparison letters caused substantial and durable reductions in quetiapine prescribing, with no evidence of negative effects on patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02467933.
引用
- Sacarny A, Barnett ML, Le J, et al. Effect of Peer Comparison Letters for High-Volume Primary Care Prescribers of Quetiapine in Older and Disabled Adults: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PMID: 30073273. doi:10.1001/jamapsychiatry.2018.1867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。